Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $20.2352W HIGH $38.26
Volume
1.80 M
Value Traded
34.27 M
Short % Float
27.18%
+0.12%Week
+5.46%1 Month
-17.1%3 Month
-14.84%6 Month
-60.78%5 Year
+19.33%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.65 B
EPS (TTM)
-3.39
P/E Ratio
-
Ent. Value
1.60 B
Total Shares
103.25 M
Float Shares
95.23 M
Insiders
7.81%
Institutions
97.68%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
BEAM Catalyst Timeline
Dated clinical, regulatory and corporate events for Beam Therapeutics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Beam Therapeutics Inc.
284Total events
6Upcoming
42Tier-1 (high impact)
2020 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Oral PresentationBEAM-302FiledPresentation
Updated Phase 1/2 data for BEAM-302 presented at ERS Congress 2026
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
▲Full ResultsBEAM-302FiledClinical Data
Updated Phase 1/2 clinical data for BEAM-302 in AATD presented at ERS Congress 2026
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
▲Long Term DataBEAM-302FiledClinical Data
Up to 18 months follow-up data showing durability of in vivo correction with BEAM-302
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
▲First Patient DosedBEAM-302FiledTrial
First patient dosed in global pivotal cohort of BEAM-302 trial
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
▲Enrollment Completeristo-celTrial
Dosing complete for all adult and adolescent patients in Phase 1/2 BEACON trial of Risto-cel
Sickle Cell Diseasesource ↗
▲IP Litigation RulingPM647IP / Competition
Arbitration tribunal declares PM647 within Prime Medicine's Field, no damages owed to Beam
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
◆IND SubmissionPM647IND
IND and/or CTA filing for PM647 expected in Q3 2026
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
◆Oral PresentationBEAM-302FiledPresentation
Presentation at ATS International Conference 2026 featuring BEAM-302 clinical data
alpha-1 antitrypsin deficiency (AATD)source ↗
▲Publicationristo-celPresentation
BEACON trial data published in New England Journal of Medicine
sickle cell disease (SCD)source ↗
●Trial CompletionBEAM-103Trial
Dosing completion expected in first half of 2026
healthy volunteer (ESCAPE)source ↗
▲Topline ReadoutBEAM-302FiledClinical Data
Updated safety and efficacy data for BEAM-302 announced
alpha-1 antitrypsin deficiency (AATD)source ↗
▲Equity OfferingCorporate
Strategic financing agreement with Sixth Street for up to $500 million non-dilutive capital
▲Enrollment UpdateBEAM-301FiledTrial
Enrollment initiated in second cohort of BEAM-301 trial
Glycogen Storage Disease Type Ia (GSDIa)source ↗
●Oral PresentationPresentation
Investor webcast to review PKU program, Sixth Street facility, and financial results
▲Accelerated Approval PathwayBEAM-302FiledDesignation
FDA alignment on potential accelerated approval pathway for BEAM-302 based on AAT biomarkers
alpha-1 antitrypsin deficiency (AATD)source ↗
▲FDA Feedback ReceivedBEAM-302FiledFDA Meeting
FDA acceptance into CMC Development and Readiness Pilot (CDRP) program
alpha-1 antitrypsin deficiency (AATD)source ↗
▲FDA Feedback Receivedristo-celFDA Meeting
FDA acceptance into CMC Development and Readiness Pilot (CDRP) program
sickle cell disease (SCD)source ↗
◆Topline ReadoutBEAM-302FiledClinical Data
Data from dose-escalation portions of Part A and Part B of BEAM-302 trial expected in early 2026
alpha-1 antitrypsin deficiency (AATD)source ↗
▲Accelerated Approval PathwayBEAM-302FiledDesignation
FDA alignment on potential accelerated approval pathway for BEAM-302
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
◆Oral PresentationBEAM-101Presentation
Updated data from BEACON trial of BEAM-101 to be presented at ASH Annual Meeting
sickle cell disease (SCD)source ↗
▲Manufacturing Milestoneristo-celCMC / Inspection
Manufacturing of all doses completed
sickle cell disease (SCD)source ↗
◆Trial InitiationBEAM-103Trial
Initiate Phase 1 healthy volunteer study of BEAM-103 antibody by YE 2025
sickle cell disease and beta-thalassemiasource ↗
▲Program DiscontinuationCorporate
Pfizer collaboration ended; Pfizer opted in to license for a liver-targeted development candidate
▲Partnership / LicenseCorporate
Pfizer opted in to exclusive worldwide license for liver-targeted development candidate
▲First Patient DosedBEAM-103Trial
First subject dosed in Phase 1 healthy volunteer trial of BEAM-103
healthy volunteersource ↗
▲First Patient DosedBEAM-302FiledTrial
First patient dosed in Part B of BEAM-302 Phase 1/2 trial
alpha-1 antitrypsin deficiency (AATD) with mild to moderate liver diseasesource ↗
▲Partnership / LicenseCorporate
Bristol Myers Squibb announced acquisition of Orbital Therapeutics; Beam holds 17% stake
◆Topline ReadoutBEAM-101Clinical Data
Updated data from BEACON Phase 1/2 trial expected by end of 2025
sickle cell diseasesource ↗
●Trial InitiationBEAM-103Trial
Initiation of Phase 1 healthy volunteer trial of BEAM-103 expected by end of 2025
▲RMATBEAM-101Designation
FDA granted RMAT designation to BEAM-101 for SCD
sickle cell disease (SCD)source ↗
▲Enrollment UpdateBEAM-302FiledTrial
17 patients dosed in BEAM-302 Phase 1/2 trial as of August 1, 2025
alpha-1 antitrypsin deficiencysource ↗
▲Enrollment CompleteBEAM-101Trial
Enrollment complete in adult and adolescent cohorts of BEACON trial
sickle cell diseasesource ↗
▲First Patient DosedBEAM-101Trial
First adolescent patient dosed in BEACON Phase 1/2 trial of BEAM-101
sickle cell diseasesource ↗
▲Enrollment Completeristo-celTrial
Adult and adolescent cohorts of BEACON trial fully enrolled
sickle cell disease (SCD)source ↗
◆Oral PresentationBEAM-101Presentation
Updated data from BEACON Phase 1/2 trial of BEAM-101 accepted for presentation at EHA 2025
sickle cell diseasesource ↗
◆Enrollment MilestoneBEAM-101Trial
Expect to dose 30 patients in BEACON trial by mid-2025
sickle cell diseasesource ↗
▲Orphan Drug DesignationBEAM-101Designation
FDA granted orphan drug designation to BEAM-101
sickle cell diseasesource ↗
▲First Patient DosedBEAM-301FiledTrial
First patient dosed in Phase 1/2 trial of BEAM-301
glycogen storage disease type Iasource ↗
▲RMATBEAM-302FiledDesignation
FDA granted RMAT designation to BEAM-302
alpha-1 antitrypsin deficiencysource ↗
▲Orphan Drug DesignationBEAM-302FiledDesignation
FDA granted orphan drug designation to BEAM-302
alpha-1 antitrypsin deficiencysource ↗
◆Oral PresentationBEAM-302FiledPresentation
Updated data from Part A of Phase 1/2 trial to be presented at medical conference
alpha-1 antitrypsin deficiency (AATD)source ↗
Past FDA Catalysts and PDUFA Decisions
How BEAM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | PM647 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C45 / 100
Pipeline Score
$263M
Pipeline Value
Richly Valued
Valuation Signal
5
Drugs Scored
0.1x
rNPV / MCap
Top 27%
Small Cap(rank 179 of 660)
Percentile Rank
Beam Therapeutics Inc. carries a moderate pipeline score (45/100), with $405M risk-adjusted pipeline value, led by BEAM-302 in Alpha 1-Antitrypsin Deficiency (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BEAM-302 Small moleculeNCT06389877 | Alpha 1-Antitrypsin Deficiency | Phase 1 | RECRUITING | 192 | May 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every BEAM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| BEAM-302 RMATOrphan | Alpha-1 Antitrypsin Deficiency (AATD) | Phase 1/2 | 2026-09-08 | sustained AAT protein production under normal physiological control with follow-up extending up to 18 monthsRead More | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Cavanagh Bethany JOfficer (SVP, Finance and Treasurer) | Sell | -187 50,984 held | $24.41 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in BEAM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Kynam Capital Management, LP | 5.4 % | 97.50 M | 2.84 M | -22.85% ( -841.39 K) |
BEAM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How BEAM ranks across every disease it competes in
Competitive Position is a premium feature
See how BEAM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialBEAM News
BEAM▼ -9.5%on this news
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics presented updated clinical data for BEAM-302 at the ERS Congress 2026. The trial indicates that BEAM-302 may serve as a one-time treatment for Alpha-1 Antitrypsin Deficiency (AATD), effectively addressing both lung and liver manifestations. Data show sustained AAT protein production under normal physiological control with follow-up extending up to 18 months.
Read more →BEAMBeam Therapeutics Appoints Eric Foster as Chief Commercial Officer
Beam Therapeutics has appointed Eric Foster as its Chief Commercial Officer. Foster will oversee the company's commercial strategy as it prepares for the potential launch of its product candidate, risto-cel, in 2027. With over 25 years of experience in biotechnology, Foster's leadership is expected to enhance Beam's commercial capabilities and support multiple product launches.
Read more →BEAMBeam Therapeutics to Participate in Upcoming September 2026 Investor Conferences
Beam Therapeutics Inc. has announced its participation in several investor conferences, including fireside chats. This engagement reflects the company's commitment to connecting with the investment community and discussing its innovations in precision genetic medicines through base editing. The events are set to take place in September 2026.
Read more →BEAM▲ +9.4%on this news
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics has reported its financial results for the second quarter of 2026, highlighting a successful dosing of the first patient in the global pivotal cohort of the BEAM-302 trial for Alpha-1 Antitrypsin Deficiency. Additionally, the updated Phase 1/2 clinical data has been selected for a late-breaking oral presentation at the European Respiratory Society Congress. The company also completed dosing for all patients in the BEACON trial of Risto-cel in Sickle Cell Disease.
Read more →BEAMBeam Therapeutics to Present Updated Data from Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) in Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026
Beam Therapeutics is set to present updated data from its Phase 1/2 trial of BEAM-302, targeting Alpha-1 Antitrypsin Deficiency (AATD). The presentation will occur at the European Respiratory Society (ERS) Congress in 2026. Additionally, the company will host an investor webcast to discuss the clinical data on September 8, 2026.
Read more →BEAM▲ +5.1%on this news
Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration
Beam Therapeutics has received FDA clearance for its investigational new drug application for BEAM-304, aimed at treating phenylketonuria (PKU). This innovative program utilizes a platform-based approach to develop multiple mutation-specific base editors. The company plans to initiate a Phase 1/2 trial to establish clinical proof of concept for this therapy. Preclinical data indicates promising results in normalizing plasma phenylalanine levels.
Read more →BEAMBeam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference
Beam Therapeutics presented new clinical data for BEAM-302 at the ATS 2026 conference, highlighting its potential to durably restore normal AAT function in patients with alpha-1 antitrypsin deficiency (AATD). The Phase 1/2 trial results indicate significant efficacy and safety, with plans for accelerated FDA approval. The company aims to enroll more patients for further evaluation.
Read more →BEAMBeam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference
Beam Therapeutics Inc. will present at the 2026 RBC Capital Markets Healthcare Conference on May 20, 2026. CEO John Evans is scheduled to speak at 10:30 a.m. ET in New York. The presentation will be available via a live webcast and archived for 60 days. Beam focuses on precision genetic medicines using base editing technology.
Read more →BEAMBeam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026
Beam Therapeutics announced that it will present updated biomarker data from the BEACON Phase 1/2 trial of risto-cel for sickle cell disease at EHA2026. The data indicates risto-cel's potential to improve red blood cell health and function, with results comparable to sickle cell trait. This underscores the therapy's promising profile for patients with severe sickle cell disease.
Read more →BEAMBeam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile,
Beam Therapeutics has reported promising first quarter 2026 financial results and advancements in its clinical trials. The topline data for BEAM-302 in alpha-1 antitrypsin deficiency indicates a strong safety and efficacy profile, with plans to initiate a pivotal cohort later this year. Additionally, the company anticipates filing a Biologics License Application for risto-cel in sickle cell disease by year-end 2026. Beam's financial resources are robust, with $1.2 billion in cash, ensuring operational stability through mid-2029.
Read more →BEAM▲ +14%on this news
Beam Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Announces New Liver-Targeted Genetic Disease Program in Phenylketonuria (PKU)
Beam Therapeutics has reported its financial results for Q4 and year-end 2025 while announcing the introduction of BEAM-304, a new program targeting phenylketonuria (PKU). This program aims to utilize advanced base editing technology to correct mutations associated with PKU, offering potential long-term solutions for patients. Additionally, Beam's financial strategy includes a significant non-dilutive capital investment to support its development efforts, including a Biologics License Application for risto-cel expected by the end of 2026. The company is well-positioned for clinical and regulatory milestones over the next few years.
Read more →BEAM▲ +22.3%on this news
Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition
Beam Therapeutics announced its strategic priorities for 2026, focusing on its liver-targeted genetic disease and hematology programs. The company has aligned with the FDA on a potential accelerated approval pathway for BEAM-302, targeting Alpha-1 Antitrypsin Deficiency, and plans to submit a Biologics License Application for its risto-cel therapy by late 2026. Beam's strong financial position with $1.25 billion in cash is expected to support operations and facilitate the progress of its clinical programs through 2029. The company continues to innovate in the field of precision genetic medicines, showcasing advancements in their ongoing trials and pipeline development.
Read more →BEAM▼ -6.2%on this news
Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
Beam Therapeutics has reported its third-quarter 2025 financial results, highlighting continued progress in its clinical trials, including BEAM-302 and BEAM-101. The company has a robust cash position of $1.1 billion, expected to fund operations until 2028, amidst ongoing research efforts in alpha-1 antitrypsin deficiency and sickle cell disease. Additionally, Beam is involved in a strategic acquisition scenario with Orbital Therapeutics, potentially enhancing its market position, but faces challenges with ongoing financial losses and rising R&D expenditures. Updated data presentations are scheduled for upcoming industry events, signaling active engagement in the biotech field.
Read more →BEAMBeam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics released its second quarter 2025 financial results, highlighting significant clinical progress in its BEAM-302 trial for alpha-1 antitrypsin deficiency (AATD) with 17 patients dosed. The company reported durable correction of the disease-causing mutation and emphasized a well-tolerated safety profile. Beam also indicated cash reserves to sustain operations through 2028, with upcoming data expected from BEAM-302 and BEAM-101 clinical trials by early and late 2025 respectively. Additionally, BEAM-302 has received RMAT and orphan drug designations from the FDA, underscoring its potential for AATD treatment.
Read more →BEAM▼ -19.3%on this news
Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam's Second Clinical Stage In Vivo Editing Program
Beam Therapeutics reported its first quarter 2025 financial results, highlighting significant clinical advancements and a solid financial position. The company announced the dosing of the first patient in the Phase 1/2 study of BEAM-301 for glycogen storage disease type Ia and continued progress in its BEAM-302 program for alpha-1 antitrypsin deficiency. Financially, Beam ended the quarter with $1.2 billion in cash and equivalents, supported by a recent $500 million financing. Additionally, updates on other clinical programs are anticipated in 2025, presenting opportunities for further advancements.
Read more →BEAM▼ -9.8%on this news
Beam Therapeutics Announces Pricing of Underwritten Offering
Beam Therapeutics announced the pricing of an underwritten offering of over 16 million shares priced at $28.48 each, projected to raise about $500 million. The proceeds will be aimed at advancing their base editing technology and funding various clinical trials, such as for alpha-1 antitrypsin deficiency and sickle cell disease. The offering is expected to finalize on March 11, 2025, subject to standard closing conditions. Major financial institutions, including J.P. Morgan and Citigroup, are managing the offering.
Read more →BEAM▼ -9.8%on this news
Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation
Beam Therapeutics announced promising initial results from their Phase 1/2 trial of BEAM-302 for treating Alpha-1 Antitrypsin Deficiency (AATD). Initial data shows that BEAM-302, after a single dose, can significantly increase levels of functional Alpha-1 Antitrypsin while reducing the levels of harmful mutant proteins. The treatment appears to be well tolerated, with no serious adverse effects reported. Further results are anticipated at a medical conference in late 2025 as the trial continues.
Read more →BEAMBeam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts
Beam Therapeutics has reported its fourth-quarter and year-end financial results for 2024, achieving its adult enrollment target in the BEACON trial for sickle cell disease therapy BEAM-101. The company is set to present updated data from this trial in mid-2025 while also progressing on other therapies, including BEAM-302 for alpha-1 antitrypsin deficiency. Although the company holds $850.7 million in cash to sustain operations through 2027, it experienced notable net losses and a decrease in cash reserves compared to the previous year. The upcoming milestones and existing cash position indicate a well-structured plan moving forward in 2025.
Read more →BEAMPRECISION GENETIC MEDICINES THROUGH BASE EDITING NASDAQ: BEAM January 2025 Cautionary note regarding forward-looking statements This presentation contains forward-looking statements within the meaning of the Private Secu
Beam Therapeutics is showcasing its advancements in precision genetic medicines through base editing, highlighting the progress of its pipeline candidates such as BEAM-101, BEAM-302, and others. The company's initiatives aim to provide potential one-time curative therapies for diseases like sickle cell disease and alpha-1 antitrypsin deficiency. While Beam has a robust financial position to support its operations, it acknowledges various risks associated with regulatory approvals and clinical trial timelines. The company is set to present significant data and updates throughout 2025, reflecting its leadership in the gene editing field.
Read more →BEAMBeam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting All Seven Patients Treated with BEAM-101 Achieved Hemogl
Beam Therapeutics has announced promising data from the BEACON Phase 1/2 clinical trial of its investigational therapy, BEAM-101, for patients with sickle cell disease. All seven patients in the study experienced a robust increase in fetal hemoglobin and reductions in sickle hemoglobin, without reports of vaso-occlusive crises following treatment. Initial safety results are consistent with existing therapies, and further data are expected to provide insights into the long-term benefits of BEAM-101. Beam plans to present additional findings during the upcoming American Society of Hematology annual meeting.
Read more →About Beam Therapeutics Inc.
Headquarters26 LANDSDOWNE STREET, CAMBRIDGE, MA, 02139
Founded2017
BIOPHARMAWATCH ELITE PLUS
Trade the next BEAM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime